PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2015 | 75 | 4 |

Tytuł artykułu

Metabolic enhancer piracetam attenuates rotenone induced oxidative stress: a study in different rat brain regions

Warianty tytułu

Języki publikacji

EN

Abstrakty

EN
Piracetam is clinically being used nootropic drug but the details of its neuroprotective mechanism are not well studied. The present study was conducted to assess the effects of piracetam on rotenone induced oxidative stress by using both ex vivo and in vivo test systems. Rats were treated with piracetam (600 mg/kg b.w. oral) for seven constitutive days prior to rotenone administration (intracerebroventricular, 12µg) in rat brain. Rotenone induced oxidative stress was assessed after 1 h and 24 h of rotenone administration. Ex vivo estimations were performed by using two experimental designs. In one experimental design the rat brain homogenate was treated with rotenone (1 mM, 2 mM and 4 mM) and rotenone+piracetam (10 mM) for 1 h. While in second experimental design the rats were pretreated with piracetam for seven consecutive days. On eighth day the rats were sacrificed, brain homogenate was prepared and treated with rotenone (1 mM, 2 mM and 4 mM) for 1h. After treatment the glutathione (GSH) and malondialdehyde (MDA) levels were estimated in brain homogenate. In vivo study showed that pretreatment of piracetam offered significant protection against rotenone induced decreased GSH and increased MDA level though the protection was region specific. But the co-treatment of piracetam with rotenone did not offer significant protection against rotenone induced oxidative stress in ex vivo study. Whereas ex vivo experiments in rat brain homogenate of piracetam pretreated rats, showed the significant protection against rotenone induced oxidative stress. Findings indicated that pretreatment of piracetam significantly attenuated the rotenone induced oxidative stress though the protection was region specific. Piracetam treatment to rats led to its absorption and accumulation in different brain regions as assessed by liquid chromatography mass spectrometry/mass spectrometry. In conclusion, study indicates the piracetam is able to enhance the antioxidant capacity in brain cells in region specific manner. The study is also revealing the rationale for its clinical use in cognitive impairment and other neurological diseases.

Wydawca

-

Rocznik

Tom

75

Numer

4

Opis fizyczny

p.399-411,fig.,ref.

Twórcy

autor
  • Toxicology Division, CSIR-Central Drug Research Institute, Lucknow, India
autor
  • Department of Biochemistry and Biophysics, University of California, San Francisco, California, USA
autor
  • Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India
  • Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India
autor
  • Toxicology Division, CSIR-Central Drug Research Institute, Lucknow, India
autor
  • Toxicology Division, CSIR-Central Drug Research Institute, Lucknow, India

Bibliografia

  • Candelario-Jalil E, Ajamieh HH, Sam S, Martinez G, Fernandez OSL (2000) Nimesulide limits kainate-induced oxidative damage in the rat hippocampus. Eur J Pharmacol 390: 295–298.
  • Chaves RS, Melo TQ, D’Unhao AM, Farizatto KL, and Ferrari MF (2013) Dynein c1h1, dynactin and syntaphilin expression in brain areas related to neurodegenerative diseases following exposure to rotenone. Acta Neurobiol Exp (Wars) 73: 541–556.
  • Colado MI, O’Shea E, Granados R, Misra A, Murray TK, Green AR (1997) A study of the neurotoxic effect of MDMA (“ectasy”) on 5-HT neurons in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol 121: 827–833.
  • Costa RA, Fernandes MP, de Souza-Pinto NC, Vercesi AE (2013) Protective effects of L-carnitine and piracetam against mitochondrial permeability transition and PC3 cell necrosis induced by simvastatin. Eur J Pharmacol 701: 82–86.
  • Deneke SM, Fanburg BL (1989) Regulation of cellular glutathione. Am J Physiol 1: 163–173.
  • Facino RM, Carini M, Aldini G, Saibene L, Morelli R (1995) Differential inhibition of superoxide, hydroxyl and peroxyl radicals by nimesulide and its main metabolite 4-hydroxynimesulide. Arzneimittelforschung 45: 1102– 1109.
  • Fedi M, Reutens D, Dubeau F, Andermann E, D’Agostino D, Andermann F (2001). Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 58(5): 781–786.
  • Giurgea CE (1982) The nootropic concept and its prospective implications. Drug Dev Res 2: 441–446.
  • Glowinski J, Iversen LL (1966) Regional studies of catecholamines in the rat brain. The disposition of [3H] norepinephrine [3H] dopamine and [3H] DOPA in various regions of the brain. J Neurochem 13: 655–670.
  • Goswami P, Swarnkar S, Harsoliya MS, Singh S, Nath C, Sharma S (2011) Attenuation of DNA damage, A key step in neuroprotective effect of piracetam against 6-hydroxydopamine induced neuronal death in SHSY5Y cells. J Pharm Res 4: 1716–1719.
  • Gupta S, Verma DK, Biswas J, Rama Raju KS, Joshi N, Wahajuddin, Singh S (2014) The metabolic enhancer piracetam attenuates mitochondrion-specific endonuclease G translocation and oxidative DNA fragmentation. Free Radic Biol Med 73: 278–290.
  • He Z, Liao Y, Zheng M, Zeng FD, Guo LJ (2008) Piracetam improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Cell Mol Neurobiol 28: 613–627.
  • He Z, Hu M, Zha YH, Li ZC, Zhao B, Yu LL, Yu M, Qian Y (2014). Piracetam ameliorated oxygen and glucose deprivation-induced injury in rat cortical neurons via inhibition of oxidative stress, excitatory amino acids release and P53/Bax. Cell Mol Neurobiol 34(4): 539–547.
  • Horvath B, Marton Z, Halmosi R, Alexy T, Szapary L, Vekasi J, Biro Z, Habon T, Kesmarky G, Toth K (2002) In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin Neuropharmacol 25: 37–42.
  • Jain A, Martensson J, Stole E, Auld PA, Meister A (1991) Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci U S A 88: 1913–1917.
  • Jordaan B, Oliver DW, Dormehl IC, Hugo N (1996) Cerebral blood flow effects of piracetam, pentifylline, and nicotinic acid in the baboon model compared with the known effect of acetazolamide. Arzneimittelforschung 46: 844–847.
  • Jose LM, Olivenza M, Moro MA, Lizasoain I, Lorenzo P, Rodrigo J, Leza JC (2001) Glutathione depletion, lipid peroxidation and mitochondrial dysfunction are induced by chronic stress in rat brain. Neuropsychopharmacology 24: 420–429.
  • Keil U, Scherping I, Hauptmann S, Schuessel K, Eckert A, Müller WE (2006) Piracetam improves mitochondrial dysfunction following oxidative stress. Br J Pharmacol 147: 199–208.
  • Leuner K, Kurz C, Guidetti G, Orgogozo JM, Müller WE (2010) Improved mitochondrial function in brain aging and Alzheimer disease – the new mechanism of action of the old metabolic enhancer piracetam. Front Neurosci 7: 44.
  • Lowry OH, Rosebrough NJ, Farr AL (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275.
  • Malykh AG, Sadaie MR, (2010). Piracetam and piracetamlike drugs: from basic science to novel clinical applications to CNS disorders. Drugs 70(3): 287–312.
  • Marí M, Morales A, Colell A, García-Ruiz C, FernándezCheca JC (2009) Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 11: 2685– 2700.
  • Muller WE, Koch S, Scheuer K, Rostock A, Bartsch R (1997) Effects of piracetam on membrane fluidity in the aged mouse rat and human brain. Biochem Pharmacol 53: 135–140.
  • Navarro SA, Serafim KG, Mizokami SS, Hohmann MS, Casagrande R, Verri WA Jr (2013) Analgesic activity of piracetam: effect on cytokine production and oxidative stress. Pharmacol Biochem Behav 105: 183–192.
  • Paxinos G, Watson C (1982) The Rat Brain in Stereotaxic Coordinates (2nd ed.) Academic Press, New York, NY, USA. p. 83–97.
  • Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini AF (2003) The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol 66: 1499–1503.
  • Radi R, Beckman JS, Bush KM, Freeman BA (1991) Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem 266: 4244–4250.
  • Rybka J, Kupczyk D, Kędziora-Kornatowska K, Pawluk H, Czuczejko J, Szewczyk-Golec K, Kozakiewicz M, Antonioli M, Carvalho LA, Kędziora J (2011) Agerelated changes in an antioxidant defense system in elderly patients with essential hypertension compared with healthy controls. Redox Rep 16: 71–77.
  • Sendrowski K, Sobaniec W, Stasiak-Barmuta A, Sobaniec P, Popko J (2015) Study of the protective effects of nootropic agents against neuronal damage induced by amyloidbeta (fragment 25–35) in cultured hippocampal neurons. Pharmacol Rep 67(2): 326–331.
  • Sharma M, Gupta YK (2003) Effect of alpha lipoic acid on intracerebroventricular streptozotocin model of cognitive impairment in rats. Eur Neuropsychopharmacol 13: 241–247.
  • Singh S, Goswami P, Swarnkar S, Singh SP, Wahajuddin, Nath C, Sharma S (2011) A study to evaluate the effect of nootropic drug-piracetam on DNA damage in leukocytes and macrophages. Mutat Res 726: 66–74.
  • Swarnkar S, Goswami P, Kamat PK, Patro IK, Singh S, Nath C (2013) Rotenone-induced neurotoxicity in rat brain areas: a study on neuronal and neuronal supportive cells. Neuroscience 230: 172–183.
  • Swarnkar S, Singh S, Mathur R, Patro IK, Nath C (2010) A study to correlate rotenone induced biochemical changes and cerebral damage in brain areas with neuromuscular coordination in rats. Toxicology 272: 17–22.
  • Swarnkar S, Singh S, Sharma S, Mathur R, Patro IK, Nath C (2011) Rotenone induced neurotoxicity in rat brain areas, a histopathological study. Neurosci Lett 501: 123–127.
  • Swarnkar S, Tyagi E, Agrawal R, Singh MP, Nath C (2009) A comparative study on oxidative stress induced by LPS and rotenone in homogenates of rat brain regions. Environ Toxicol Pharmacol 27: 219–224.
  • Testa CM, Sherer TB, Greenamyre JT (2005). Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res 134: 109–118.

Typ dokumentu

Bibliografia

Identyfikatory

Identyfikator YADDA

bwmeta1.element.agro-976fc436-a647-469d-91d7-1b6a8f047e4b
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.